Video summary

Week 01: Lecture 03: Polymers used in Drug Delivery Systems

Main summary

Key takeaways

Educational

Main ideas / lessons from the lecture

  • Purpose of polymers in drug delivery systems (DDS):

    • Polymers are collections of monomers. By repeating monomer units—and sometimes combining different monomers as co-polymers or forming tri-block polymers—they can be engineered to:
      • Modify drug release profiles
      • Enhance bioavailability
      • Improve stability
      • Enable targeted delivery to specific sites
    • Compared with other materials (e.g., lipids, inorganic materials), polymers are highlighted for their strong role in controlled release and stability.

  • Classification framework for polymers used in DDS:

    • Based on source:
      • Natural polymers
      • Synthetic polymers
      • Semi-synthetic polymers
    • Based on biodegradability:
      • Biodegradable polymers
      • Non-biodegradable polymers
    • Based on response to stimuli (covered elsewhere in detail in the lecture):
      • “Smart polymers” responding to:
        • pH
        • Temperature
        • Enzymatic triggers
        • Magnetic responsiveness

Detailed content: polymer types and key examples

1) Natural polymers (examples + typical uses)

  • Chitosan (subtitle spelling inconsistent; presented as “Kitoan”)

    • Used for biomedical / novel DDS
    • Forms systems for release modification and encapsulation
    • Applications include:
      • Tissue engineering
      • Wound healing
    • Noted property:
      • Positive charge → promotes mucoadhesion (interaction with mucin)
    • Targeting examples mentioned:
      • Nose-tech delivery (unclear phrasing)
      • Colon targeting

  • Alginates / sodium alginate

    • Source: seaweed
    • Used in:
      • pH-sensitive gels
      • Oral and injectable nano-carriers

  • Gelatin

    • Source: collagen

  • Zein (subtitle includes unclear text, likely transcription error; “zanthan comeum,” possibly xanthan gum)

    • Source: bacterial

  • Other natural polymers listed:

    • Xyloglucon (unclear transcription)
    • Starch
    • Hyaluronic acid
      • Used in gene delivery, topical, and ophthalmic formulations

  • Formulation types / delivery contexts mentioned:

    • Nanoparticles and microspheres
    • Sustained-release tablets
    • Colon-specific drug delivery
    • Tablets/implants using starch
    • Colon targeting (using pH/mucus-related concepts)

2) Synthetic polymers

  • Key advantages over natural polymers:

    • Controlled architecture
    • Higher purity
    • Less risk of heavy metal / impurity contamination from natural sources
    • Can be structurally modified (e.g., conjugation with other moieties such as lipids)

  • Examples mentioned:

    • PLGA (poly(lactic-co-glycolic acid))
    • PCL (polycaprolactone)
    • PEG (“udraid polythine glycol,” described as polyethylene glycol–type; unclear transcription)
    • Poloxamers / Pluronics

  • Biodegradability:

    • Synthetic examples are stated as biodegradable
    • Also noted: non-biodegradable hydrophilic polymers can support targeting strategies like enteric coating and colon targeting
    • A thermosensitive polymer approach mentioned using Pluronics

3) Semi-synthetic polymers

  • Examples mentioned:

    • Carboxymethyl cellulose (CMC)
    • HPMC
    • Ethyl cellulose
    • Hydroxyethyl starch

  • Concept:

    • Semi-synthetic polymers are derived from natural polymers but chemically modified to suit DDS needs.

  • Applications mentioned:

    • Tablets
    • Injectables
    • Matrix systems
    • Ophthalmic
    • Topical formulations

Biodegradability (why it matters + how it happens)

  • Why biodegradability is crucial in DDS:

    • If a polymer cannot degrade, it may need later removal (as an implant), or it can cause toxicity / incompatibility.

  • Definition given:

    • Biodegradability = ability of material to break down into simpler, non-toxic components, such as:
      • water
      • carbon dioxide
      • methane/bio gas (bio-gas mentioned)

  • Mechanisms of degradation listed:

    • Enzymatic
    • Microbial
    • Hydrolysis
    • Environmental conditions

  • Subtle point conveyed:

    • Degradation products/metabolites should be non-toxic and suitable for human use.

Ideal properties of polymers for drug delivery (structured list)

  1. Biocompatibility

    • Polymer should be compatible after administration:
      • Should not trigger immune or toxic responses
    • Typical pre-approval testing mentioned:
      • Hemocompatibility tests (e.g., check that hemoglobin/RBC components do not leak)
      • Assess aggregation of blood components on the polymer surface
    • Determine the concentration range that remains non-toxic.

  2. Biodegradability

    • Degradation should:
      • produce metabolites that are not toxic
      • allow a controlled degradation rate
      • support prolonged / modified release
    • Avoid polymer/drug incompatibility:
      • polymer must not degrade in a way that reduces drug efficacy
      • in preformulation, test drug stability after polymer exposure

  3. Drug–polymer compatibility

    • During preformulation:
      • test different polymer/drug concentrations
      • check for incompatibilities after treatment
      • ensure the drug is not degraded by the polymer environment
    • Confirm adequate properties for the intended dosage form.

  4. Mechanical strength

    • Important for:
      • topical formulations
      • tissue engineering
      • systems like implants/scaffolds where structural integrity matters

  5. Mucoadhesive performance (for mucoadhesive DDS)

    • Only polymers with effective interaction with mucin/mucus should be used for mucoadhesion-based targeting.
    • Outcomes described:
      • increases retention time
      • increases residence time
      • leads to drug release at the target site
    • Example given:
      • Eye drops vs mucoadhesive system: conventional drops clear with tear fluid; mucoadhesive systems retain longer due to mucus adherence.

  6. Stimulus responsiveness

    • Depending on polymer type:
      • pH-sensitive or temperature-sensitive behavior can support targeted drug delivery (including cancer targeting and other diseases).
    • Used to help design controlled and targeted systems (microspheres/nanoparticles/hydrogels mentioned).

Applications of polymer-based DDS (what they enable)

  • Hydrogels

    • Used for:
      • wound healing
      • transdermal delivery (via patches)
    • Properties mentioned:
      • swell in water
      • respond to stimuli

  • Transdermal delivery

    • Use polymers to create noninvasive patches
    • Expected benefit:
      • improved patient compliance
    • Must consider transdermal-relevant drug properties.

  • Colon targeting

    • Polymers used to release/respond in colon pH
    • Benefits mentioned:
      • helps avoid first-pass metabolism
      • mucus-related interaction can improve retention/bioavailability

  • Polymer–drug conjugates

    • Concept:
      • drug is covalently linked to a polymer → becomes a new molecule
    • Claimed effects:
      • increased solubility
      • improved permeability
      • improved half-life/bioavailability
      • better targeting to the desired site
    • (Examples of “many polymers” are implied; specific ones not fully listed here.)

Non-drug delivery applications of polymers

  • Tissue engineering & regenerative medicine

    • Polymers used for 3D scaffolds
    • Scaffold use:
      • support cell growth in 3D

  • Wound healing support

    • Improved healing using biodegradable/hydrogel systems

  • Surgical / orthopedic support materials

    • Mentioned:
      • sutures
      • staples
      • implants
      • bone fixation devices

Advantages and limitations (organized)

Advantages of polymers in DDS (as stated)

  • Modified drug release
  • Targeted drug delivery via tailored polymer-based DDS designs
  • Biocompatible and biodegradable (highlighted as major advantages)
  • Protection of drug molecules from harsh environments (e.g., via enteric coating / pH-responsive strategies)
  • Versatile routes of administration:
    • oral, injection, topical (as dosage forms when properly formulated)
  • Enhanced solubility and bioavailability
    • especially with polymeric micelles/encapsulation strategies
  • Mucoadhesion benefits
    • improved retention at mucus-rich sites
    • improved patient compliance

Limitations / challenges of polymers in DDS (as stated)

  • Polymer toxicity
    • must test safety concentration before formulation
  • Manufacturing complexity
    • especially when combining multiple polymers (2–3), increasing cost
  • Stability issues
    • some polymers can degrade under storage conditions (PLGA specifically mentioned):
      • may require refrigeration
  • Limited drug loading
    • especially with hydrophilic/water-soluble or natural polymers
  • Risk of burst release
    • particularly with water-soluble/natural polymers → can reduce efficacy
  • Batch-to-batch variability
    • mitigated by scalable/controlled processing:
      • continuous methods
      • improved process control parameters
      • optimized scalable manufacturing

Speakers / sources featured

  • Dr. Satish Dawanapelli — lecturer (student professor, Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology Mumbai per subtitle text; exact institute name transcribed with errors).
  • No other speakers or named external sources are clearly credited in the provided subtitles.
  • Music/Applause — appears as non-voice stage elements in the transcript.

Original video